Stock Deep Dive · 2026-07-29
Celltrion (068270) closed at ₩180,000, up 1.47% on the day. Year-to-date return is +4.4%, sitting at 27% of its 52-week range. Next earnings: 2026-08-06 (in 8 days). Listed in Seoul — for USD-based investors, KRW moves add an FX layer on top of the stock’s local return.
|
Close
₩180,000
+1.47% · YTD +4.4%
|
Market Cap
₩41.28T
Biotechnology
|
Forward P/E
24.2x
PER 32.6x
|
52-wk Range
27%
High ₩239,048 · Low ₩158,500
|
🔍 At a Glance
Celltrion has quietly delivered one of Korea’s more resilient earnings stories, with quarterly revenue up 36.0% YoY and a fat 29.8% TTM operating margin, backed by a broadening biosimilar lineup (Remsima, Truxima, Yuflyma, Vegzelma, Steqeyma and more) gaining share in Europe. Yet the stock still sits 27% into its 52-week range and is down 7.4% over three months, with a rich forward PER of 24.2 and PBR of 2.4 suggesting the market has already priced in much of the growth, while ROE of 7.3% looks modest relative to those multiples.
🏢 How It Makes Money
Celltrion’s engine is biosimilars — lower-cost copies of blockbuster biologics across autoimmune disease, oncology, and other categories. Its expanding portfolio (Yuflyma, Steqeyma, Avtozma, Omlyclo, Eydenzelt, Zymfentra) is designed to capture share as originator patents expire, particularly in the U.S. and Europe, where headlines point to widening European penetration. The KRW1.7 trillion share cancellation also signals management’s confidence in capital allocation and shareholder value.
📈 Quarterly Results — Is Business Growing?
| Quarter | Revenue | Op. Income | Net Income | Op. Margin |
|---|---|---|---|---|
| 25Q1 | ₩841.9B | ₩149.4B | ₩108.7B | 17.7% |
| 25Q2 | ₩961.5B | ₩229.9B | ₩61.2B | 23.9% |
| 25Q3 | ₩1.03T | ₩301.4B | ₩331.4B | 29.3% |
| 25Q4 | ₩1.33T | ₩475.8B | ₩528.4B | 35.8% |
| 26Q1 | ₩1.14T | ₩321.9B | ₩346.1B | 28.1% |
| 26Q2* | ₩1.39T | ₩451.8B | ₩370.2B | 32.4% |
* 26Q2 figures come from the company’s preliminary earnings disclosure filed with Korea’s DART on 2026-07-27. They are unaudited and will be replaced once the reviewed quarterly or half-year report is filed.
Latest-quarter revenue up +45.0% versus the same quarter a year ago.
💡 Korea Market 101
⚖️ Valuation — Cheap or Expensive?
| Metric | Value | How to read it |
|---|---|---|
| P/E (trailing) | 32.6x | Price vs last 12 months’ earnings |
| P/E (forward) | 24.2x | Price vs next 12 months’ expected earnings — growth hopes baked in |
| P/S | 9.2x | Price vs revenue — for high-growth names with thin profits |
| P/B | 2.4x | Price vs book value — below 1x means priced under liquidation value |
| EV/EBITDA | 26.6x | Enterprise value (incl. debt) vs cash generation |
Peer comparison
| Name | Mkt Cap | P/E | Fwd P/E | P/S |
|---|---|---|---|---|
| Celltrion | ₩41.28T | — | 24.2x | 9.2x |
| SAMSUNG BIOLOGICS | ₩68.46T | — | 30.4x | 14.2x |
| Alteogen | ₩15.12T | — | 37.6x | 74.2x |
💡 Korea Market 101
🎯 Street Consensus
- Price target (mean): ₩263,450
- Target high / low: ₩330,000 / ₩200,000
- Implied upside: +46.4%
- Rating: Buy (1.5/5)
- Analysts covering: 24
- Next earnings: 2026-08-06
💡 Korea Market 101
📉 Price Action — Technical Check
| Indicator | Value | How to read it |
|---|---|---|
| RSI (14d) | 55.4 | Above 70 overbought · below 30 oversold |
| vs 60-day MA | +1.8% | Above/below the medium-term trend |
| vs 200-day MA | -2.7% | Above/below the long-term trend |
| Golden/death cross | 50-day below 200-day (bearish alignment) | 50-day MA crossing above (golden) or below (death) the 200-day |
| Volume (vs 20d avg) | 2.7x | 2x+ means a spike in market attention |
💡 Korea Market 101
📰 Recent News
- Celltrion, Inc. Revenue Breakdown – KRX:068270 — TradingView
- Celltrion defies South Korea selloff as strong earnings lift outlook – CHOSUNBIZ — Chosunbiz
- Celltrion : Reports Q2 2026 Revenue of KRW 1.3937Tn and Operating Profit of KRW 451.8Bn; Record Quarterly Revenue as New Product Growth and Cost Improvements Boost Profitability — marketscreener.com
- Korea roundup: Alteogen, Celltrion lead biotech deals — BioWorld News
- Celltrion retires W1.7tr shares in record cancellation — The Korea Herald
- Celltrion Widens Europe Share, Eyes Profit Beat — Businesskorea
💡 Korea Market 101
🔭 Scenarios & What to Watch
Bulls will point to the analyst consensus target of ₩263,450 (buy-rated, 24 analysts) — well above the current ₩180,000 — implying meaningful re-rating potential if margin momentum from record Q2 revenue (₩1.39T) and operating profit (₩451.8B) continues. Bears may flag the -9.6% six-month slide and stretched EV/EBITDA of 26.6x as vulnerable to any growth disappointment. Watch the next earnings release on 2026-08-06 for confirmation of margin trends, European share gains, and pipeline progress; FX-sensitive USD investors should also monitor won volatility given Celltrion’s export exposure.
Next earnings on 2026-08-06 (in 8 days) — guidance usually decides the stock’s direction more than the reported quarter.
💡 Korea Market 101
📚 All stock analysis · More on Celltrion · Market report for this session
Stock report · published 2026-07-29 16:00 KST
For information only — a summary of public data, not a recommendation to buy or sell any security. Source data (Yahoo Finance and others) may be delayed or contain errors. All investment decisions are your own responsibility.
Leave a Reply